Ruxolitinib (Jakafi) Dosing and Monitoring
For myelofibrosis, start ruxolitinib at 15 mg twice daily if platelets are 100-200 × 10⁹/L or 20 mg twice daily if platelets are >200 × 10⁹/L; for polycythemia vera, start at 10 mg twice daily regardless of platelet count (provided platelets are ≥100 × 10⁹/L). 1
Starting Doses Based on Indication and Platelet Count
Myelofibrosis
The FDA-approved starting doses are strictly platelet-dependent 1:
- Platelets 50-100 × 10⁹/L: Start 5 mg twice daily
- Platelets 100-200 × 10⁹/L: Start 15 mg twice daily
- Platelets >200 × 10⁹/L: Start 20 mg twice daily
NCCN guidelines align with these recommendations 2, emphasizing that certain clinical situations may support initiating at lower doses with subsequent adjustments.
Polycythemia Vera
Start at 10 mg twice daily for all patients with adequate platelet counts (≥100 × 10⁹/L) 1. This is the standard FDA-approved dose for second-line treatment after hydroxyurea intolerance or inadequate response 3, 4.
Baseline Monitoring Requirements
Before initiating therapy, obtain 2:
- Complete blood count (CBC)
- Comprehensive metabolic panel with uric acid and LDH
- Baseline MPN-SAF TSS-10 symptom assessment (for myelofibrosis)
Ongoing Monitoring Strategy
Monitor CBC every 2-4 weeks until doses are stabilized, then as clinically indicated 2. In the first 4-6 weeks, weekly monitoring is advisable, particularly for patients with advanced disease 5.
After month 3, monitoring every 3 months is appropriate if blood counts remain stable 5.
Dose Adjustments for Myelofibrosis
For Patients Starting with Platelets ≥100 × 10⁹/L
Dose reductions 1:
- If platelets fall to 75-100 × 10⁹/L: Reduce by 5 mg twice daily
- If platelets fall to 50-75 × 10⁹/L: Reduce by an additional 5 mg twice daily
- If platelets <50 × 10⁹/L: Hold drug
Treatment interruption and restart 1:
- Hold for platelets <50 × 10⁹/L or ANC <0.5 × 10⁹/L
- Restart when platelets ≥50 × 10⁹/L and ANC ≥0.75 × 10⁹/L
- Resume at dose 5 mg twice daily lower than pre-interruption dose
For Patients Starting with Platelets 50-100 × 10⁹/L
More stringent thresholds apply 1:
- Hold for platelets <25 × 10⁹/L or ANC <0.5 × 10⁹/L
- For platelets 25-35 × 10⁹/L with <20% decline over 4 weeks: Decrease by 5 mg once daily
- For platelets 25-35 × 10⁹/L with ≥20% decline over 4 weeks: Decrease by 5 mg twice daily
Restart after recovery (platelets >35 × 10⁹/L, ANC >0.75 × 10⁹/L) at 5 mg once or twice daily below the dose that caused interruption 1.
Dose Escalation for Insufficient Response
Do not increase doses during the first 4 weeks 2, 1. After 4 weeks, if there is insufficient spleen reduction or symptom improvement, increase by 5 mg twice daily increments at 4-week intervals to maximum:
- 10 mg twice daily (if platelets <100 × 10⁹/L)
- 25 mg twice daily (if platelets >100 × 10⁹/L)
Requirements for dose escalation 1:
- Platelets >125 × 10⁹/L at 4 weeks and never <100 × 10⁹/L
- ANC >0.75 × 10⁹/L
- No dose reductions or interruptions in prior 4 weeks
Discontinue if no response after 6 months 2, 1.
Dose Adjustments for Polycythemia Vera
Dose Reductions Based on Blood Counts 1
- Hemoglobin 10-12 g/dL OR platelets 75-100 × 10⁹/L: Consider dose reduction to avoid interruptions
- Hemoglobin 8-10 g/dL OR platelets 50-75 × 10⁹/L: Reduce by 5 mg twice daily (if on 5 mg twice daily, reduce to 5 mg once daily)
- Hemoglobin <8 g/dL OR platelets <50 × 10⁹/L OR ANC <1.0 × 10⁹/L: Hold drug
Restarting After Interruption
The restart dose depends on the most severe hematologic parameter 1:
- Hemoglobin 8-10 g/dL OR platelets 50-75 × 10⁹/L OR ANC 1-1.5 × 10⁹/L: Restart at 5 mg twice daily (or 5 mg twice daily less than interruption dose)
- Hemoglobin 10-12 g/dL OR platelets 75-100 × 10⁹/L OR ANC 1.5-2 × 10⁹/L: Restart at 10 mg twice daily (or 5 mg twice daily less than interruption dose)
- Hemoglobin ≥12 g/dL OR platelets ≥100 × 10⁹/L OR ANC ≥2 × 10⁹/L: Restart at 15 mg twice daily (or 5 mg twice daily less than interruption dose)
Continue for at least 2 weeks; if stable, may increase by 5 mg twice daily 1.
Critical Pitfalls to Avoid
Premature discontinuation: Most cytopenias occur in the first 8-12 weeks and are manageable with dose adjustments 6, 7. Platelet counts typically stabilize and hemoglobin levels gradually return toward baseline after this period.
Inadequate starting dose: Real-world data show that starting at reduced doses is associated with worse overall survival in myelofibrosis (median OS 52.6 vs 78.2 months) 8. However, this must be balanced against baseline platelet counts—never exceed FDA-recommended starting doses based on platelet thresholds.
Maintaining subtherapeutic doses: Doses ≥10 mg twice daily are associated with clinically meaningful symptom improvement and spleen reduction 6, 9. Gradual dose escalation after the first 4 weeks is appropriate if response is insufficient and blood counts permit.
Abrupt discontinuation: Symptoms may return to pretreatment levels within approximately one week following discontinuation 2. Consider gradual tapering when discontinuing for reasons other than thrombocytopenia or neutropenia.
Special Monitoring Considerations
Lipid parameters: Assess 8-12 weeks after initiation; ruxolitinib increases total cholesterol, LDL, and triglycerides 2.
Infections: Monitor for opportunistic infections, including tuberculosis and hepatitis B reactivation 2. Screen for latent TB before starting therapy.
Spleen size: Monitor by palpation or imaging to assess response 2.
Bleeding: Interrupt treatment for bleeding requiring intervention regardless of platelet count 1. Resume at prior dose if underlying cause is controlled; otherwise, resume at lower dose.